Table 4.
Genetic alterations of PTEN in human cancers.
| Primary Tumor Tissues | Mutations (%) 1 | Copy Number Variations (%) 1 | Gene Expression (%) 1 | ||
|---|---|---|---|---|---|
| Gain | Loss | Over | Under | ||
| Adrenal gland | 1/816 (0.12%) | - | - | 6/79 (7.59%) | 2/79 (2.53%) |
| Autonomic ganglia | 3/1404 (0.21%) | - | - | - | - |
| Biliary tract | 92/1922 (4.81%) | - | - | - | - |
| Bone | 11/889 (1.24%) | - | - | - | - |
| Breast | 567/10,325 (5.49%) | 1/1492 (0.07%) | 31/1492 (2.08%) | 21/1104 (1.9%) | 47/1104 (4.26%) |
| – ductal carcinoma | 214/2832 (7.56%) | - | - | - | - |
| – ER-positive carcinoma | 94/1477 (6.36%) | - | - | - | - |
| – HER-positive carcinoma | 11/275 (4%) | - | - | - | - |
| – basal (triple-negative) carcinoma | 21/469 (4.48%) | - | - | - | - |
| – ER-PR-positive carcinoma | 12/403 (2.98%) | - | - | - | - |
| Central nervous system | 1040/7783 (13.36%) | - | 46/1035 (4.44%) | 19/697 (2.73%) | 146/679 (20.95%) |
| Cervix | 74/1598 (4.63%) | - | 12/299 (4.01%) | 13/307 (4.23%) | 21/307 (6.84%) |
| Endometrium | 1565/3944 (39.68%) | 1/586 (0.17%) | 19/586 (3.24%) | 50/602 (8.31) | 37/602 (6.15%) |
| – endometrioid carcinoma | 1170/2100 (55.71%) | 1/530 (0.19%) | 17/530 (3.21%) | 34/545 (6.24%) | 27/545 (4.95%) |
| Eye | 15/401 (3.74%) | - | - | - | - |
| Hematopoietic and lymphoid | 388/14,559 (2.67%) | - | - | 9/221 (4.07%) | 1/221 (0.45%) |
| Kidney | 132/3451 (3.82%) | - | 4/995 (0.4%) | 19/600 (3.17%) | 33/600 (5.5%) |
| Large intestine | 476/8913 (5.34%) | - | 11/718 (1.53%) | 14/610 (2.3%) | 46/610 (7.54%) |
| Liver | 184/2979 (6.18%) | 1/663 (0.15%) | 10/663 (1.51%) | 10/373 (2.68%) | 13/373 (3.49%) |
| Lung | 319/9054 (3.52%) | 1/1006 (0.1%) | 21/1006 (2.09%) | 28/1019 (2.75%) | 83/1019 (8.15%) |
| – adenocarcinoma | 94/4362 (2.15%) | - | 2/375 (0.53%) | 13/378 (3.44%) | 23/378 (6.08%) |
| – non-small cell carcinoma | 22/1521 (1.45%) | - | - | - | - |
| – squamous cell carcinoma | 113/1554 (7.27%) | 1/500 (0.2%) | 18/500 (3.6%) | 12/502 (2.39%) | 57/502 (11.35%) |
| Meninges | 30/513 (5.85%) | - | - | - | - |
| Esophagus | 63/2117 (2.98%) | - | 4/510 (0.78%) | 9/125 (7.2%) | 10/125 (8%) |
| Ovary | 141/2831 (4.98%) | 2/684 (0.29%) | 13/684 (1.9%) | 7/266 (2.63%) | 47/266 (17.67%) |
| Pancreas | 103/3192 (3.23%) | 1/898 (0.11%) | 1/898 (0.11%) | 11/179 (6.15%) | 4/179 (2.23%) |
| Penis | 2/74 (2.7%) | - | - | - | - |
| Peritoneum | 1/225 (0.44%) | - | - | - | - |
| Pituitary | 0/89 (0%) | - | - | - | - |
| Pleura | 2/530 (0.38%) | - | 1/87 (1.15%) | - | - |
| Prostate | 393/4517 (8.7%) | 1/949 (0.11%) | 71/949 (7.48%) | 16/498 (3.21%) | 91/498 (18.27%) |
| Salivary gland | 22/623 (3.53%) | - | - | - | - |
| Skin | 309/3679 (8.4%) | - | 28/587 (4.77%) | 17/473 (3.59%) | 30/473 (6.34%) |
| Small intestine | 2/326 (0.61%) | - | - | - | - |
| Soft tissue | 59/2514 (2.35%) | - | 14/264 (5.3%) | 5/263 (1.9%) | 15/263 (5.7%) |
| Stomach | 130/2980 (4.36%) | - | 15/472 (3.18%) | 7/285 (2.46%) | 26/285 (9.12%) |
| Testis | 7/639 (1.1%) | - | 1/149 (0.67%) | - | - |
| Thymus | 0/372 (0%) | - | - | - | - |
| Thyroid | 110/3936 (2.79%) | - | 1/490 (0.2%) | 25/513 (4.87%) | 9/513 (1.75%) |
| Upper aerodigestive tract | 126/3441 (3.66%) | - | 12/520 (2.31%) | 17/522 (3.26%) | 16/522 (3.07%) |
| Urinary tract | 45/1614 (2.79%) | 1/399 (0.25%) | 8/399 (2.01%) | 7/408 (1.72%) | 20/408 (4.9%) |
| Vulva | 12/157 (7.64%) | - | - | - | - |
1 Mutated samples/total number of sample analyzed (%); -, no data. The data were derived from COSMIC v92 (released 27-AUG-20).